Data completeness
0/8 — Limited
Drug data last refreshed 14h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INNOVAR is a fixed-dose combination injectable containing droperidol (a butyrophenone antipsychotic) and fentanyl citrate (a potent opioid agonist), indicated for anesthesia and analgesia in perioperative settings. The combination provides neuroleptanalgesia, combining sedation, anxiolysis, and analgesia for patients undergoing surgical procedures. This pre-launch product from AstraZeneca targets intraoperative and postoperative pain and anxiety management.
Pre-Launch
Pre-launch stage indicates active build-out phase with team expansion expected across commercial, medical affairs, and manufacturing functions.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on INNOVAR during its pre-launch phase offers early-stage growth opportunity and exposure to product launch mechanics, regulatory approval processes, and perioperative market dynamics. Professionals joining now will shape market positioning and initial formulary placement in a specialized but established therapeutic category.
Brand ManagerMedical Science Liaison
Worked on INNOVAR at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.